[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,104,499
  • Shares Outstanding, K 231,773
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 215 M
  • EBITDA $ 224 M
  • 60-Month Beta 0.73
  • Price/Sales 4.21
  • Price/Cash Flow 14.17
  • Price/Book 5.52

Options Overview Details

View History
  • Implied Volatility 74.85% (-6.97%)
  • Historical Volatility 33.32%
  • IV Percentile 73%
  • IV Rank 32.72%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 5) 0.43 (4.68%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 196
  • Volume Avg (30-Day) 443
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 72,869
  • Open Int (30-Day) 82,607
  • Expected Range 8.66 to 9.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 1
  • High Estimate $0.16
  • Low Estimate $0.16
  • Prior Year $0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.11 +11.96%
on 06/11/26
9.33 -2.68%
on 07/10/26
+0.60 (+7.08%)
since 06/10/26
3-Month
7.45 +21.88%
on 06/02/26
11.42 -20.49%
on 04/24/26
-0.62 (-6.39%)
since 04/10/26
52-Week
7.21 +25.93%
on 03/26/26
20.46 -55.62%
on 12/12/25
-9.39 (-50.84%)
since 07/10/25

Most Recent Stories

More News
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

NEW ORLEANS , July 10, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications...

ADMA : 9.08 (-2.05%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

NEW YORK , July 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).   Such investors...

ADMA : 9.08 (-2.05%)
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , July 9, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA )...

ADMA : 9.08 (-2.05%)
INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ADMA : 9.08 (-2.05%)
ADMA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ADMA BIOLOGICS, INC. Securities Lawsuit - Contact Levi & Korsinsky

From August 2024 through March 2026, ADMA Biologics allegedly filed seven consecutive SEC reports containing false internal control certifications and omitted related party sales, while channel stuffing...

ADMA : 9.08 (-2.05%)
INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO , July 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded...

ADMA : 9.08 (-2.05%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 8, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 9.08 (-2.05%)
Lost Money on ADMA BIOLOGICS, INC. (ADMA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

ADMA Biologics projected 20% ASCENIV revenue growth in 2025, but a short-seller report alleges the real figure was a 3% decline, with the gap driven entirely by an alleged channel stuffing...

ADMA : 9.08 (-2.05%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , July 7, 2026 /PRNewswire/ --

ADMA : 9.08 (-2.05%)
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , July 7, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

ADMA : 9.08 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 9.53
2nd Resistance Point 9.43
1st Resistance Point 9.26
Last Price 9.08
1st Support Level 8.98
2nd Support Level 8.88
3rd Support Level 8.71

See More

52-Week High 20.46
Fibonacci 61.8% 15.40
Fibonacci 50% 13.83
Fibonacci 38.2% 12.27
Last Price 9.08
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.